我院服用华法林患者抗凝治疗质量评价
x

请在关注微信后,向客服人员索取文件

篇名: 我院服用华法林患者抗凝治疗质量评价
TITLE:
摘要: 目的:评价服用华法林患者的抗凝治疗质量,为加强服用华法林患者的管理提供数据支持。方法:回顾性分析符合纳入标准的214例服用华法林患者的相关临床资料。结果:所有患者服用华法林的平均时间为(321.64±189.50)d,非住院期间于我院检测国际标准化比值(INR)的平均次数为(12.01±7.03)次;抗凝治疗期间INR<2.0的占51.96%,2.0≤INR≤3.0的占39.13%,INR>3.0的占8.91%;INR目标值≤2.0的占45.33%,INR目标值=2.5的占38.32%,INR目标值≥3.0的占0.93%;平均目标范围内的时间百分比(TTR)为(50.80±22.32)%;不同年龄及不同疾病患者的TTR比较,差异均无统计学意义(P>0.05)。结论:部分服用华法林患者抗凝治疗质量较差,需加强抗凝治疗质量的管理,使抗凝安全、有效。
ABSTRACT: OBJECTIVE: To evaluate the quality of anticoagulant therapy in patients who took warfarin and provide data supporting for strengthening the management of these patients. METHODS: A retrospective analysis of related clinical data of 214 patients who meet the inclusion criteria was performed. RESULTS: The average time for patients took warfarin was (321.64±189.50) d, average times for tested INR was (12.01±7.03) times in clinic; when anticoagulant therapy, INR<2.0 accounted for 51.96%, 2.0≤INR≤3.0 accounted for 39.13%, and INR>3.0 accounted for 8.91%; patients with target INR≤2.0 accounted for 45.33%, target INR=2.5 accounted for 38.32%, and target INR≥3.0 accounted for 0.93%; the average TTR was (50.80±22.32)%; and there was no statistical significance in the TTR of different ages and diseases (P>0.05). CONCLUSIONS: The anticoagulant therapy in some patients who took warfarin shows poor quality, it needs strengthening the quality management to make it safe and effective.
期刊: 2016年第27卷第15期
作者: 李玲玲,李莹,都丽萍,李雯,梅丹
AUTHORS: LI Lingling,LI Ying,DU Liping,LI Wen,MEI Dan
关键字: 华法林;抗凝治疗;目标范围内时间百分比;国际标准化比值;质量评价
KEYWORDS: Warfarin; Anticoagulant therapy; Time in therapeutic range; International normalized ratio; Quality evaluation
阅读数: 430 次
本月下载数: 5 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!